Fei Song

Dr. Fei Song


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Bioactive Materials
Verified
Journal Article
Open access
ALAobo Liu
Aobo Liu
YQYu Qin
Yu Qin
JDJiabao Dai
Jiabao Dai
FSFei Song
Fei Song
YTYun Tian
Yun Tian
PWPeng Wen
Peng Wen
Zinc (Zn)-based biodegradable metals (BMs) fabricated through conventional manufacturing methods exhibit adequate mechanical strength, moderate degradation behavior, acceptable biocompatibility, and bioactive functions. Consequently, they are recognized as a new generation of bioactive metals and show promise in several applications. However, conventional manufacturing processes face formidable limitations for the fabrication of customized implants, such as porous scaffolds for tissue engineering, which are future direction towards precise medicine. As a metal additive manufacturing technology, laser powder bed fusion (L-PBF) has the advantages of design freedom and formation precision by using fine powder particles to reliably fabricate metallic implants with customized structures according to patient-specific needs. The combination of Zn-based BMs and L-PBF has become a prominent research focus in the fields of biomaterials as well as biofabrication. Substantial progresses have been made in this interdisciplinary field recently. This work reviewed the current research status of Zn-based BMs manufactured by L-PBF, covering critical issues including powder particles, structure design, processing optimization, chemical compositions, surface modification, microstructure, mechanical properties, degradation behaviors, biocompatibility, and bioactive functions, and meanwhile clarified the influence mechanism of powder particle composition, structure design, and surface modification on the biodegradable performance of L-PBF Zn-based BM implants. Eventually, it was closed with the future perspectives of L-PBF of Zn-based BMs, putting forward based on state-of-the-art development and practical clinical needs.

1 May 2025 in International Journal of Surgery Case Reports
Verified
Journal Article
Open access
DHDong Hu
Dong Hu
FSFei Song
Fei Song
SXSonghua Xiao
Songhua Xiao
Introduction: Giant cell tumor (GCT) of the sacrum is a rare, locally aggressive bone tumor. Surgical resection is the primary treatment, but preserving sacral nerve function remains challenging. We present a case of sacral GCT treated with a novel nerve-preserving en bloc resection technique, resulting in long-term tumor control and functional recovery. Case presentation: A 33-year-old male presented with progressive sacral pain and neurological symptoms. Imaging revealed a sacral GCT involving the S1 vertebral body and nerve root canal. The patient underwent en bloc resection with sacral nerve preservation and reconstruction, along with custom 3D-printed prosthesis implantation. Postoperative recovery was uncomplicated, with preserved bowel, bladder, and lower limb function. There was no evidence of recurrence during the 8-year follow-up period. Clinical discussion: Sacral GCTs present substantial surgical challenges due to their proximity to critical neurovascular structures. While en bloc resection effectively reduces recurrence rates, it often compromises sacral nerve function. Our technique successfully preserved key sacral nerve roots, leading to superior postoperative functional outcomes compared to conventional approaches. A review of relevant literature supports the advantages of nerve-sparing strategies in sacral tumor surgery. Conclusion: This case highlights the feasibility and benefits of sacral nerve-preserving en bloc resection for GCT. The long-term follow-up confirms durable tumor control and robust functional recovery, suggesting its potential as a preferred surgical approach for carefully select cases. Highlights:

6 July 2026 in European Spine Journal
Verified
Journal Article
Closed access
DHDong Hu
Dong Hu
WRWei Rong
Wei Rong
FSFei Song
Fei Song
SXSonghua Xiao
Songhua Xiao

14 October 2022 in Medicine
Verified
Journal Article
Open access
DHDong Hu
Dong Hu
HLHuawei Liu
Huawei Liu
BYBei Yuan
Bei Yuan
SGsuxi gu
suxi gu
KXKai Xu
Kai Xu
SXSonghua Xiao
Songhua Xiao
The first case of vertebral augmentation therapy in mainland China was reported in 2000. Since then, it has been widely used in China as a minimally invasive procedure to treat vertebral compression fractures. However, the characteristics of malpractice litigation involving vertebral augmentation therapy remains unclear. This study aims to analyze the characteristics of medical malpractice litigation involving vertebral augmentation therapy in mainland China for the past 10 years. Two online legal databases were queried for court verdicts involving vertebral augmentation therapy from Jan 2009 to Dec 2018 in mainland China. Each case file was then thoroughly reviewed and data pertaining to defendants, plaintiffs, case outcomes, allegations, and verdicts were abstracted, and descriptive analyses were performed. Level of evidence: LEVEL III. A total of 96 cases were enrolled for final analysis. The number of claims increased by five times during the past 10 years. More than two thirds (67.7%, n = 65) of the cases underwent percutaneous vertebroplasty, and 22.9% (n = 22) underwent percutaneous kyphoplasty, the rest (9.4%, n = 9) remained undefined. Paralysis was alleged in 35.4% of cases (n = 34), followed by significant physical injury (34.4%, n = 33). Cement leakage to spinal canal (44.8%, n = 43) is the most commonly cited reason for litigation, followed by incomplete informed consent (42.7%, n = 41), accidental dural puncture (20.8%, n = 20), unsatisfactory clinical outcome (18.8%, n = 18), and misdiagnosis (12.5%, n = 12). Acute pulmonary cement embolism (4.2%, n = 4), wrong-level vertebrae procedure (3.1%, n = 3) and postoperative infection (2.1%, n = 2) were less common causes for concern. Doctors successfully defended themselves only in 8 (8.3%) cases, which resulted in no indemnity payment. The rest 88 (91.7%) cases were closed with a mean verdict payout of 361,580 Yuan (51,654 US dollars). There is a quickly rising trend in the number of medical malpractice litigation involving vertebral augmentation therapy in China. Identifying the most common reasons for litigation and summarizing their characteristics may help decrease litigation rate and improve the patient experience.